Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alk-Abello ASCHIX:ALKBC 94 Net Cash per Share is kr-4.72 as of Jun. 2026. GuruFocus rates CHIX:ALKBC with a GF Score™ of 94/100 and a GF Value™ of kr225.44 (Fairly Valued). Among 747 Biotechnology companies, Alk-Abello AS ranks worse than 133868.67% on this metric.
The historical rank and industry rank for Alk-Abello AS's Net Cash per Share or its related term are showing as below:
CHIX:ALKBc's Price-to-Net-Cash is not ranked *
in the Biotechnology industry.
Industry Median: 5.23 * Ranked among companies with meaningful Price-to-Net-Cash only.
Alk-Abello AS (CHIX:ALKBc) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Alk-Abello AS Net Cash per Share Related Terms
Alk-Abello AS Net Cash per Share Historical Data
* Premium members only.
The historical data trend for Alk-Abello AS's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:ALKBC vs VRTX, REGN, RVMD: Net Cash per Share Comparison
For the Biotechnology subindustry, Alk-Abello AS's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alk-Abello AS Price-to-Net-Cash vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alk-Abello AS's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Alk-Abello AS's Price-to-Net-Cash falls into.
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Alk-Abello AS's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alk-Abello AS (CHIX:ALKBC) has a Net Cash per Share of kr-4.72 as of Jun. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Alk-Abello AS and its competitors. According to the industry distribution chart, Alk-Abello AS ranks #999999 out of 747 companies in the Biotechnology industry.
Is Alk-Abello AS's Net Cash per Share too high?
Alk-Abello AS's current Net Cash per Share is kr-4.72. Based on the distribution chart, Alk-Abello AS ranks #999999 out of 747 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Alk-Abello AS has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Alk-Abello AS's Net Cash per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alk-Abello AS ranks #999999 out of 747 companies for Net Cash per Share. This places Alk-Abello AS in the lower half of its industry. The industry median Net Cash per Share is 5.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Biotechnology company?
The median Net Cash per Share among Biotechnology companies is 5.23, based on 747 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Alk-Abello AS and its competitors. For the Biotechnology industry, the median Net Cash per Share is 5.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alk-Abello AS's current Net Cash per Share is kr-4.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alk-Abello AS stock overvalued right now?
Based on GuruFocus' analysis, Alk-Abello AS (CHIX:ALKBC) is currently considered Fairly Valued. The stock's GF Value™ is kr225.44, compared to a current price of kr221.50 — trading 1.7% below its estimated fair value. The current Net Cash per Share is kr-4.72. Alk-Abello AS's overall GF Score™ is 94/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Alk-Abello AS (CHIX:ALKBC), the current Net Cash per Share is kr-4.72 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alk-Abello AS (CHIX:ALKBC) Overvalued in 2026?
Based on GuruFocus' analysis, Alk-Abello AS stock appears to be undervalued.
The current stock price of kr221.50 is trading 1.7% below its estimated GF Value™ of kr225.44.
GuruFocus considers Alk-Abello AS to be Fairly Valued.
Key valuation signals for CHIX:ALKBC:
Net Cash per Share: kr-4.72
GF Value™: kr225.44 vs. price of kr221.50 (1.7% below fair value)
No single metric tells the full story. See the CHIX:ALKBC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.
94GF Score
Get the complete analysis for CHIX:ALKBC
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:ALKBC has been successfully added to your 
